Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2021
Subject: Update on the ONWARD pivotal Phase 3 clinical trial for AD04, a drug candidate for Alcohol Use Disorder (AUD) targeting specific genotypes.
Key Financial Metrics
This filing is a non-financial event report. The text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Clinical Trial Updates
The Company reported significant progress in the ONWARD Phase 3 trial as of February 25, 2021:
- Enrollment Status: 50% of the trial is enrolled; full enrollment is expected in the Summer of 2021.
- Screening Progress: 66% of planned screening visits completed (830 patients screened out of 1,254 expected).
- Genotype Prevalence: 32% of screened patients are genetically positive for AD04 treatment, consistent with Phase 2b and expected U.S./European prevalence.
- Enrollment Efficiency: 75% of genetically positive patients have been enrolled, exceeding the projected rate of 50%.
- Patient Retention: 86% retention rate to date, significantly higher than the projected 70%.
Guidance, Outlook, and Risks
Outlook: Management projects full trial enrollment by Summer 2021 based on current screening and enrollment rates.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trial completion. The press release is furnished and not incorporated by reference into registration statements.
Investor Verification Checklist
- Verify the final enrollment numbers and timeline against the Summer 2021 projection.
- Confirm the final patient retention rate upon trial completion.
- Review the full text of the attached Press Release (Exhibit 99.1) for detailed statistical data.
- Monitor subsequent filings for the final analysis of the ONWARD trial results.